Walleye Capital’s 9 Meters Biopharma NMTR Stock Holding History

Walleye Capital’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,500	Closed	-$176	–	1569
2021 Q1	$176	Buy	+7,500	New	+$230K	0.01%	949

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's NMTR Position: Q2 2021 in Review

Walleye Capital sold out of 9 Meters Biopharma (NMTR) in Q2 2021, closing a stake of 7,500 shares — an estimated $176 sold.

Walleye Capital first reported a position in NMTR in Q1 2021 and held it in 1 quarter. The position peaked at $176 in Q1 2021. 99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

Walleye Capital reported no remaining 9 Meters Biopharma position as of Q2 2021 after selling out during the quarter.
Walleye Capital sold 7,500 9 Meters Biopharma shares in Q2 2021, an estimated $176.
Walleye Capital first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 1 quarter.
Walleye Capital's 9 Meters Biopharma position peaked at $176 in Q1 2021.
99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on Walleye Capital's 13F filing for Q2 2021, filed 16 Aug 2021.